Spotlight
Obituaries
Classifieds
Families First
VCAs Best of Guide
News
Weather
Specialists
Sports
Business
Consumer
Health
Life
Out & About
Login
Recommended
Inside job: NC inmates accused of running phone scams targeting families for fake bail payments
Recommended
Summer maintenance tips: Do these things indoors and out to keep your home cool in summer heat
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Samsung Bioepis Co., Ltd.
Samsung Bioepis Releases Third Quarter 2025 US Biosimilar Market Report Exploring the Most-Favored-Nation (MFN) Policy and its Impact on Biosimilars
July 21, 2025
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
July 17, 2025
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis’ Second Quarter 2025 Biosimilar Market Report Highlights US Debut of Ustekinumab Biosimilars with WAC discounts over 80% and Regulatory Streamlining
April 24, 2025
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Announces US Launch of PYZCHIVA® (ustekinumab-ttwe), Biosimilar to Stelara
February 24, 2025
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
FDA Approves Samsung Bioepis’ OSPOMYV™, XBRYK™ (denosumab-dssb), a Biosimilar to Prolia and Xgeva
February 15, 2025
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.